Developing a novel therapeutic target in XP11.2 translocation renal cell carcinoma

Ended Project Grant Awarded Last action

Award ID
W81XWH2210399
Recipient
Awarding agency
Obligated
$694,200

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Funding
  • $347,100.00 Federal
  • $347,100.00 Non-federal
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of the Army Medical Command awarded a $694,200 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research developing a novel therapeutic target in XP11.2 translocation renal cell carcinoma. The grant was awarded on July 1, 2022 under the Military Medical Research and Development program (CFDA 12.420), with a completion date of June 30, 2025.

Through this funding, Dfci will conduct research to investigate medical solutions for renal cell carcinoma, specifically focusing on developing a novel therapeutic target for the rare XP11.2 translocation subtype. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions for battlefield medicine and other health issues.

Quick answers

Who received award W81XWH2210399?

W81XWH2210399 was awarded to Dana-Farber Cancer Institute, Inc. by Medical Command (Department of the Army) on July 1, 2022.

How much is award W81XWH2210399 worth?

$694,200 has been obligated on W81XWH2210399: $347,100 in federal funding and $347,100 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login